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Idiopathic juxtafoveal retinal telangiectasis type 2 (macular telangiectasia 
type 2; MacTel) is a rare neurovascular degenerative retinal disease. To 
identify genetic susceptibility loci for MacTel, we performed a genome-
wide association study (GWAS) with 476 cases and 1733 controls of 
European ancestry. Genome-wide significant associations (P < 5 × 10-8) 
were identified at 3 independent loci (rs73171800 at 5q14.3, P = 7.74 × 10-
17; rs715 at 2q34, P = 9.97 × 10-14; rs477992 at 1p12, P = 2.60 × 10-12) and 
then replicated (P < 0.01) in an independent cohort of 172 cases and 1134 
controls. The 5q14.3 locus is known to associate with variation in retinal 
vascular diameter, and the 2q34 and 1p12 loci have been implicated in the 
glycine/serine metabolic pathway. We subsequently found significant 
differences of blood serum levels of glycine (P = 4.04 × 10-6) and serine (P = 
2.48 × 10-4) between MacTel cases and controls.  
 
MacTel cases typically present at 40-60 years with abnormal right-angled 
juxtafoveolar capillaries and parafoveal telangiectasias. It is an uncommon 
disease with a 0.0045-0.1% population prevalence and no obvious sex bias1-3. 
Retinal lesions typically co-present with MacTel, including retinal transparency, 
outer retinal and choroidal neovascularization, lamellar holes or foveal cysts, 
photoreceptor dysfunction, minimal exudation, yellow-white parafoveal crystals, 
and retinal pigment epithelial (RPE) pigmentation abnormalities and atrophy. 
Central vision impairment and decreased visual acuity are the usual clinical 
outcomes. MacTel is a bilateral disease, but asymmetry of the eyes for disease 
severity and presence of lesions is possible. The lesions also occur in 0.06-1.18% 
of the general population2. 
 
Risk factors for MacTel are largely unknown, however associations have been 
observed with smoking2,4, diabetes5,6, high BMI6, hypertension6 and obesity6.  
 
Observations of MacTel affected monozygotic twins4,7-9, and multiplex families 
with vertical transmissions of MacTel1,5,9-12, suggest a genetic etiology for the 
disease. The late-age of onset, low penetrance and variable phenotype as 
exemplified by asymptomatic affected relatives9, and positive and negative 
misdiagnoses, complicate the discovery of genetic variants predisposing to 
MacTel. We previously screened 27 candidate genes in 8 unrelated MacTel cases 
but found no causative mutations13. Linkage analysis of 17 families with MacTel 
individuals identified a 15.3Mb locus on chromosome 1q41-42.2 (LOD=3.45), 
however sequencing of the underlying genes revealed no causative mutations14. 
 
Results 
 
Discovery GWAS stage 
 
The GWAS discovery stage included genotype data for 6,312,048 single 
nucleotide polymorphisms (SNPs) after quality control and imputation 
(including 1,093,805 SNPs genotyped on the Illumina Omni SNP chips) in 476 
MacTel cases and 1,733 controls (see Table 1 and Online Methods). This 
sample size was large enough to achieve power of at least 0.90 for risk variants 
with allele frequencies of 0.10-0.70, assuming a population prevalence of 0.001 
for MacTel and an odds ratio (OR) effect size of 2 for the risk allele 
(Supplementary Figure 1), but the power drops to 0.53 for an odds ratio 1.5, as 
expected from a GWAS of modest size. Samples were of European descent as 
confirmed by comparative analysis with the 1000 Genomes project samples 
(Supplementary Figure 2). Population substructure was assessed using 
principal component analysis (PCA; Supplementary Figures 2-4). Heritability 
on the liability scale for MacTel was estimated as 0.21 or 0.74, given prevalence 
rates of 0.0045% and 0.1%, respectively. The GWAS was performed with logistic 
regression modeling with the first principal component (PC1) as a covariate. 
Quantile-quantile plots (Supplementary Figure 5) demonstrate the correction 
of inflation likely due to population substructure (without PC1 genomic λ = 
1.141; with PC1 genomic λ = 1.035). Additional PCs increased the genomic 
inflation factor with no difference to the key results, and is likely due to the small 
sample size. 
 
SNPs at six loci surpassed the genome-wide significance threshold (Figure 1 and 
Supplementary Tables 2 and 3). Three of these loci (at 1p36.22, 3p24.1 and 
7p21.3) were discounted as false positives after failing technical validation steps 
(Online methods). The remaining three loci (at 5q14.3, 2q34 and 1p12) 
included 149 SNPs that reached genome-wide significance (Figure 2). Seven of 
the 149 SNPs (Table 2a) were genotyped in an independent ethnically European 
cohort of 172 MacTel cases and 1,134 controls. Selecting SNPs for replication 
was governed by the ability to create TaqMan assays. We ensured that at least 
one actual genotyped, rather than imputed, SNP was selected at each locus. As it 
was not possible to perform PCA analysis on the replication cohort, the 
replication analysis was performed without covariates. SNPs at all three loci 
replicated association (P < 0.01; Table 2a). 
 
Locus 5q14.3 
 
At 5q14.3, 116 SNPs were genome-wide significant within a 400kb region, 
including the strongest associated variant in our study, rs73171800 (per-allele 
OR = 2.41, 95% CI=1.96-2.96; P = 7.74 × 10-17). Two SNPs were selected for 
replication at this locus, rs17478824 and rs73173548, and both associated with 
MacTel in our independent cohort (Table 2a). Among the other genome-wide 
significant SNPs at this locus were rs2194025 (per-allele OR = 2.31, 95% CI = 
1.88-2.84; P = 1.97 × 10-15) and rs17421627 (per-allele OR = 2.43, 95% CI = 1.93-
3.06; P = 3.51 × 10-14). All five of these variants are in strong LD (pair-wise r2 = 
0.73-0.98) and their minor alleles confer risk to MacTel. Similarly, the minor 
alleles of both rs2194025 and rs17421627 have been associated with increased 
retinal venular and arterial calibers (Table 3a)15,16. A broader region 
encompassing this 5q14.3 locus is implicated in capillary malformation [OMIM 
163000] and hereditary benign telangiectasia [OMIM 187260], two cutaneous 
vasculature abnormality traits that may be variable expressions of the same 
disorder with possible intra-familial comorbidity17-19. Hereditary benign 
telangiectasia has been linked to a 7Mb region of 5q14.1-5q14.317. Capillary 
malformations have been linked to a 19Mb region of 5q14.1-5q1518,20, and 
germline mutations of the gene RAS p21 protein activator (GTPase activating 
protein) 1 (RASA1) were identified as the likely cause for the disorder, albeit 
with phenotypic variability21-24. Murine knock-out models for RASA1 are 
embryonic lethal and display vascular abnormalities25. A microdeletion of 5q14.3 
that includes the genes RASA1 and myocyte enhancer factor 2C (MEF2C) is also 
implicated in capillary malformations26. Our top associated SNP rs73171800 is 
intergenic at this locus, and the broader associated region is within the bounds of 
the 5q14.3 microdeletion, but does not include RASA1 or MEF2C, which are 
~1Mb proximal and 100kb distal respectively. The nearest genes are TMEM161-
B, TMEM161-B-AS1, LINC102546226 and LINC00461, which are largely 
uncharacterised. The role of RASA1 in angiogenesis and capillary malformations 
makes it an interesting candidate for MacTel. However, MEF2C is closer to our 
locus, endothelially expressed, and involved in early murine vascular 
development27. MEF2C haploinsufficiency causes several neurological disorders, 
including cortical malformations, epilepsy and mental retardation28,29. Mef2c is 
involved in murine synaptic development and regulation of synaptic 
transmissions30. Knock-out Mef2c murine models are embryonic lethal31 and 
display vascular abnormalities27, including tissue dependent lumen size 
variability and defective vascular remodeling32. With respect to the late onset 
characteristic of MacTel, initial vasculogenesis in Mef2c null mice is reported 
normal, but anomalies arise later on in development, albeit still during 
embryogenesis32. Vascular endothelial growth factor A (VEGFA)33, a key player in 
angiogenesis, controls MEF2C expression in retinal epithelial cells. An anti-
angiogenic role for MEF2C during stress conditions has been suggested34. 
Epithelial cell-specific Mef2c null mice suppress retinal vascular degeneration 
and promote retinal vessel regrowth in response to oxygen-induced retinopathy, 
but not during normal unstressed retinal vasculature development34. Mef2c 
retinal-specific regulation is controlled by an alternative promoter regulated by 
the transcription factor neural retina leucine zipper (Nrl)35. Null Nrl mice lack 
rod function36, and mutations of NRL cause retinitis pigmentosa 27 [OMIM 
613750]37. 
 
Locus 2q34 
 
At 2q34 an 83kb region contained 21 variants reaching genome-wide 
significance and included the gene carbamoyl-phosphate synthase 1, 
mitochondrial (CPS1). This gene produces a rate-limiting mitochondrial enzyme 
that performs the first step of the urea cycle, converting ammonia and hydrogen 
carbonate into carbamoyl phosphate (Figure 3). Mutations of CPS1 cause 
carbamoylphosphate synthetase I deficiency [OMIM 237300] and may lead to 
death by hyperammonemia38. Our most significant SNP at this locus, rs715 (per-
allele OR = 0.50, 95% CI = 0.42-0.60; P = 9.972 × 10-14), resides within the 3’-
untranslated region (3’-UTR) of CPS1. We replicated associations with rs715 and 
rs4673553, another genome-wide significant SNP at this locus, in our 
independent cohort (Table 2a). We found the major allele of rs715 confers risk 
towards MacTel. Other GWASs have associated rs715 with several blood 
metabolite levels39-42, in particular the major allele with decreased glycine39,40,42-
44 and serine42 (Table 3a). Our estimates for the rs715 effect sizes for MacTel are 
comparable to those for glycine levels42,43 (Supplementary Figure 6). Another 
SNP at this locus, rs2216405, has also been associated with blood plasma glycine 
levels45,46 and metabolic ratios involving glycine47, and approached genome-wide 
significance in our study (per-allele OR = 0.54, 95% CI = 0.43-0.68; P = 9.426 × 
10-8). These three SNPs are in moderate LD (pair-wise r2 = 0.27-0.48). The 
variant rs1047891 (renamed from rs7422339) causes a threonine to asparagine 
missense mutation within CPS1 and has been associated with blood plasma 
levels of glycine48,49, other metabolites48,50-58, blood flow56 and vasodilator 
response56. In our study rs1047891 was imputed, and whilst it was excluded due 
to a low imputed genotype call rate (93.4%), it would otherwise have been 
highly significant with the remaining available data (P = 1.784 × 10-11). There is 
strong LD between rs715 and rs1047891 (pair-wise r2 = 0.97). Several studies 
report a marked sex effect with CPS1 associations, with females showing a 
stronger association for rs715 with glycine levels43,44, and rs1047891 with 
homocysteine levels54,55. We also observe a sex-interaction with MacTel at this 
locus (Supplementary Table 4 and Online methods). We find that females are 
at nearly twice greater risk of MacTel for each additional copy of the rs715 risk 
allele (female specific per risk allele OR = 2.58, 95% CI = 2.00-3.36; male specific 
per risk allele OR = 1.40, 95% CI = 1.08-1.81). Our estimates for the rs715 sex 
specific effect sizes for MacTel are comparable to those for glycine levels43 
(Supplementary Figure 6). 
 
Locus 1p12 
 
At 1p12, a region of 46.4kb contained 12 genome-wide significant SNPs. We 
replicated this signal in our independent cohort with the imputed SNP rs483180 
(Table 2a). This region includes the genes phosphoglycerate dehydrogenase 
(PHGDH) and 3-hydroxy-3-methylglutaryl-CoA synthase 2, mitochondrial 
(HMGCS2). GWASs have associated blood plasma serine levels with intronic 
PHGDH variants43,45, including our most significant discovery stage SNP at this 
locus, rs477992 (per-allele OR = 1.70, 95% CI = 1.47-1.97; P = 2.60 × 10-12), and 
also rs478093 (per-allele OR = 1.67, 95% CI = 1.44-1.94; P = 2.89 × 10-11). Here, 
we find the minor alleles of rs477992 and rs478093 confer risk for MacTel, and 
the same alleles are associated with decreased serine levels in other studies 
(Table 3a)43,45. PHGDH produces a rate-limiting enzyme that performs the first 
step of the phosphorylated pathway of serine biosynthesis, converting 3-
phosphoglycerate into phosphohydroxy pyruvate (Figure 3). PHGDH mutations 
may lead to PHGDH deficiency [OMIM 601815], a severe neuropathological 
disorder with reduced plasma and cerebrospinal fluid serine levels59. HMGCS2 
encodes mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase (HMG-CoA 
synthase-2), an enzyme integral to ketogenesis. Mutations of HMGC2 lead to 
hypoketotic hypoglycemia due to HMG-CoA synthase-2 deficiency60. 
 
Suggestive loci 
 
There were 25 loci that showed suggestive evidence for association to MacTel 
(10-5 > P > 5 × 10-8; Supplementary Table 2). Given our associations with CPS1 
and PHGDH, two genes implicated in serine and glycine blood plasma levels, we 
explored our 25 suggestive loci for overlap with GWAS studies for these 
metabolite levels39,40,42,43,45, and identified the loci at 3q21.3 and 7p11.2 (Figure 
4). 
 
At 3q21.3, rs1107366 has been associated with blood plasma glycine-to-serine 
ratios and clamp-based insulin sensitivity43, and rs10934753 with homocysteine 
levels and incident ischemic stroke58. Here, these two specific SNPs are not 
associated with MacTel (rs1107366, P = 0.021; rs10934753, P = 0.072), however 
two other SNPs at this locus are suggestively associated, rs9820286 (per-allele 
OR = 0.61, 95% CI = 0.49-0.75; P = 5.38 × 10-6) and rs9880406 (per-allele OR = 
0.63, 95% CI = 0.52-0.77; P = 8.98 × 10-6). While rs1107366 and rs10934753 are 
in strong LD (r2 = 0.86) and so are rs9820286 and rs9880406 (r2 = 0.88), the LD 
between these two pairs is very low (r2 < 0.012), suggesting they are tagging two 
separate signals. We were able to replicate the association to MacTel with 
rs9880406 in our independent replication cohort (Table 2b). This locus lies 
between the genes aldehyde dehydrogenase 1 family, member L1 (ALDH1L1) 
and Kruppel-like factor 15 (KLF15). ALDH1L1 is a well characterized gene that 
encodes the cytosolic enzyme 10-formyltetrahydrofolate dehydrogenase which 
catalyzes the conversion of 10-formyltetrahydrofolate into tetrahydrofolate and 
CO2 or formic acid (Figure 3)61. ALDH1L1 is a highly specific antigenic marker of 
astrocytes62, a type of glial cell critical for retinal angiogenesis during 
development63-65. Transcriptome analysis suggests that astrocytes have an 
enrichment of metabolic pathways for amino acids such as serine, glycine and 
cysteine, and pathways for the production and processing of glutamate into 
glutamine for transport to neurons62. Mutations of another aldehyde 
dehydrogenase, ALDH3A2, may cause Sjögren-Larsson syndrome [OMIM 
270200], a multifaceted neurological disorder with juvenile macular 
dystrophy66. Unlike other maculopathies, MacTel and Sjögren-Larsson syndrome 
have co-occurring blue light reflectance abnormalities and retinal crystalline 
deposits. KLF15 is a transcription factor that regulates the gene low density 
lipoprotein receptor-related protein 5 (LRP5), mutations of which have been 
associated with the dysplastic retinal vasculature disorder exudative 
vitreoretinopathy 4 [OMIM 603506]67. 
 
At 7p11.2, rs4947534 and rs4948102 are associated with blood plasma serine 
levels42 and homocysteine levels58, respectively. We find suggestive genome-
wide significance for both rs4947534 (per-allele OR = 1.44, 95% CI = 1.23-1.68; 
P = 5.38 × 10-6) and rs4948102 (per-allele OR = 1.46, 95% CI = 1.25-1.70; P = 
2.25 × 10-6) in our discovery stage. Furthermore, our strongest signal at this 
locus is with rs4948102. We selected the SNPs rs4535700 and rs11238389 for 
replication testing and both were nominally significant (P < 0.01). The variants 
rs4947534, rs4948102 and rs11238389 are in perfect LD (r2 = 1) and in very 
high LD with rs4535700 (r2 > 0.94). The minor allele of these SNPs is associated 
with MacTel risk, and similarly the minor allele of rs4947534 is associated with 
reduced serine levels42 and increased homocysteine levels58 (Table 3b). Both 
rs4947534 and rs4948102 are within the gene phosphoserine phosphatase 
(PSPH), the protein product of which catalyzes the final step in the synthesis of 
serine by converting phosphoserine into serine (Figure 3). PSPH mutations may 
cause phosphoserine phosphatase deficiency, a syndrome with multiple clinical 
features including reduced plasma levels of serine68. 
 
These suggestive loci require validation in independent cohorts. 
 
Prediction modeling 
 
Our final model incorporated the three validated and two suggestive loci with 
additive effects, PC1 and one interaction term between sex and 2q34 (Online 
Methods). Additive modeling was applied since univariate logistic regression 
analysis showed it had no significant improvement at these 5 loci when 
compared to the dominant or recessive models (Supplementary Table 5). Since 
the inclusion of PC1 makes only a nominal improvement to the prediction model 
in the discovery cohort (Supplementary Table 6), and because we could not 
derive PC1 for the replication cohort, we estimated the probability of MacTel for 
each sample in the training set (discovery cohort; Supplementary Figures 7-9) 
and validation set (replication cohort; AUC = 0.679; Supplementary Figures 10-
12) without PC1. We produced ROC curves (Supplementary Figures 13 and 
14), and computed positive predictive values (PPVs) and negative predictive 
values (NPVs) (Supplementary Table 7 and Supplementary Figures 15 and 
16) based on these predictions. 
 
Metabolomics analysis 
 
Blood serum levels of 799 metabolites, including glycine and serine, were 
compared between 50 MacTel cases and 50 independent controls matched for 
age, sex, ethnicity and diabetes status (Online methods). Student’s T-tests were 
highly significant for both glycine (T = -6.98; P = 3.51 × 10-10) and serine (T = -
5.39; P = 4.79 × 10-7). Given an observed inflation in our results (Supplementary 
Figure 17), we applied a correction akin to “genomic control” with an inflation 
factor of 1.753 (Pglycine = 4.04 × 10-6; Pserine = 2.48 × 10-4). Serum levels were lower 
in the MacTel cases than the controls (glycine log2(fold change) = -0.541; serine 
log2(fold change) = -0.382). Of all 799 metabolites, glycine and serine were 
ranked first and third most significant, respectively. Another glycine/serine 
pathway amino acid, namely threonine, was the second most significant 
metabolite, thereby reinforcing our glycine and serine results. Sample genotype 
data was not available. 
 
In-silico variant functional exploration 
 
We utilized the online GTEx Project69 portal to assess for eQTL signatures the 
SNPs showing at least suggestive association (P < 10-5) at each of the three 
validated and two suggestive loci (Online Methods, Table 3, Supplementary 
Tables 8 and 9 and Supplementary Figures 18-22). The SNPs at 2q34 and 
3q21.3 did not yield any cis eQTLs. 
 
At 1p12, SNPs with strongest association to MacTel also showed strongest 
association to gene expression levels, with eQTLs observed in two tissues each 
for both ZNF697 and PHGDH. Interestingly, for PHGDH, the direction of effect was 
tissue-specific. 
 
At 5q14.3, MacTel risk alleles associated with increased expression of 
TMEM161B-AS1, the antisense RNA to TMEM161B, in nearly every tissue tested. 
The genome-wide significant 5q14.3 MacTel risk SNPs (P < 5 × 10-8) were not 
however driving the majority of these eQTL associations, instead it was the SNPs 
showing suggestive association to MacTel (10-5 > P > 5 × 10-8). This suggests that 
while our MacTel risk SNPs are indeed affecting the expression of TMEM161B-
AS1, they may be having a stronger unobserved functional effect either on 
TMEM161-AS1 or other genes. 
 
eQTLs at the suggestive 7p11.2 locus were observed in multiple genes for a 
limited number of tissues, and the direction of effect was gene specific. Similar to 
the 1p12 locus, the SNPs with greatest association to MacTel risk also had 
greatest association to gene expression levels. 
  
Methylation and H3K4me3 histone modification architecture around the five loci 
was analyzed in the UCSC Genome browser (Supplementary Figures 18-22). 
H3K4me3 was selected due to its known strong association with transcriptional 
activity. At the 1p12 locus, there is a strong H3K4me3 signature and a moderate 
unmethylated DNA signature around the strongest associated MacTel SNPs at 
the start of PHGDH. This supports the eQTL results and suggests these SNPs may 
affect expression of PHGDH. At 2q34 and the suggestive 3q21.3 locus there are 
no remarkable H3K4me3 signatures, but a weak methylation signature is evident 
at 2q34 indicative of gene silencing.  At 5q14.3, there is a small but strong 
H3K4me3 mark at the most strongly associated MacTel risk SNPs downstream of 
TMEM161-AS1. Finally, at 7p11.2 the suggestive MacTel risk SNPs do not overlay 
any H3K4me3 modification or methylation signatures, but they do lie 
immediately adjacent to such signatures, suggesting they could be influencing 
the DNA structure by virtue of their proximity. 
 
Interpretation of these results is difficult given that we do not have any strong a 
priori expectation of the particular tissues to be of interest for MacTel, and the 
absence of eye tissue in the GTEx resource. 
 
Discussion 
 
Here, we identified three robustly validated and two suggestive genetic loci for 
MacTel. Whilst these loci include several plausible candidate genes, they account 
for only ~5% of the estimated heritability, suggesting more loci await discovery. 
 
We neither find association to any candidate genes we previously screened nor 
to any genes within the linkage region we previously reported (here, the most 
significant discovery stage signal within the linkage region was with 
rs17352829; P = 9.83 × 10-5)13,14. A rat model for MacTel carrying an insertion-
deletion mutation within the gene Crb1 has been described70, however we find 
no associated signal at this locus either. 
 
Misdiagnoses can occur between MacTel and age-related macular degeneration 
(AMD). Hence, we searched for any overlap between our top association signals 
and those previously reported for AMD71-73. Amongst our suggestive association 
signals we find the TIMP metallopeptidase inhibitor 3 (TIMP3)/synapsin III 
(SYN3) locus at 22q12.3 (Supplementary Table 2). TIMP3 is associated with 
both AMD and another maculopathy, Sorsby fundus dystrophy (SFD) [OMIM 
136900], which presents earlier in life than AMD but shares some clinical 
features74. Remarkably, the TIMP3/SYN3 locus has also been suggestively 
associated with serine and glycine levels (see The Metabolomics GWAS 
Server42,45). 
 
Major cell types of the retina include vascular, neuronal cells (rods and cones) 
and glial cells (microglia, Müller glia and astrocytes). Glial cells envelop the 
neurons and provide them with a homeostatic environment, supporting their 
survival, and serving as an intermediary with blood vessels75,76. Müller glial cells 
remove neurotransmitters, including glutamate and glycine, from synaptic 
spaces to prevent eventual neurotoxicity and enable continued synaptic 
functioning. Müller cells also detoxify ammonia by expressing the enzyme 
glutamate-ammonia ligase (glutamine synthetase)75,76. Unlike retinal neuronal 
cells, healthy Müller cells are particularly resilient to stress, including anoxia, 
hypoglycemia and ischemia. Dysfunctional Müller cells could therefore lead to 
the pathological outcomes observed in MacTel. Indeed, we have previously 
reported abnormalities of Müller cells with MacTel77,78 and observed MacTel 
characteristics following Müller cell ablation79. 
 
Retinal neurovascular coupling is important for the maintenance of local 
functionality, homeostasis and regulation of local blood supply80. The 
neurovascular unit that facilitates this function includes neurons, pericytes, 
endothelial cells and glia. Astrocytes and Müller glia regulate blood flow by 
vasoconstriction and vasodilation81, hence aberrant functioning of these cells 
may affect this regulated control of vascular caliber and thereby blood flow82. 
Since we previously reported an association between MacTel and increased 
retinal vasculature calibers82, our findings here linking MacTel risk alleles at 
2q34 and 5q14.1 with increased vasodilation, or venular and arterial calibers, 
respectively (Table 3a), may be highly relevant. 
  
We found that the MacTel risk alleles at 1p12, 2q34 and suggestive locus 7p11.2 
were previously associated with decreased serine levels (Table 3), and we find 
serine and glycine serum levels significantly lower in MacTel cases. The serine 
pathway involves ammonia and glutamate substrates, and it is plausible that a 
perturbation of this system due to defective enzyme activity may prevent Müller 
glia from performing their multifaceted functions normally. Altered expression 
of PHGDH, PSHP, ALDH1L1 or CPS1 (at 1p12, 7p11.2, 3q21.3 and 2q34, 
respectively) could lead to the observed decreases in serine levels, and 
consequently to hyperammonemia and hyper-glutamate conditions of a 
neurotoxic level, thereby causing retinal stress and damage. Müller glia and 
other cells react to retinal damage and stress by undergoing gliosis, a process 
that includes expression changes of glutamate-ammonia ligase and the induction 
of VEGFA expression. MEF2C (at 5q14.3, the strongest genome-wide associated 
locus) is under the control of VEGFA, and may normally prevent stress-induced 
angiogenesis. Hence a defective variant of MEF2C may be unable to suppress 
angiogenesis during retinal damage. 
 
Müller glia also remove neuron derived carbon dioxide by expressing carbonic 
anhydrases (CAs)75,76 which catalyze the reaction of carbon dioxide and water 
into hydrogen carbonate. One of the few drugs reported to date with a positive 
effect on MacTel is acetazolamide, by reducing cystic lesions83. Acetazolamide is 
a CA inhibitor (Figure 3). The hydrogen carbonate produced by Müller cells may 
be released into the vitreous body or blood stream76. CPS1 utilizes hydrogen 
carbonate and ammonia as substrates for the urea cycle (chiefly in the liver). 
 
Previously we showed that glycolytic pathway genes have reduced expression in 
the MacTel macula compared to either non-macula retinal tissue of the same eye 
or healthy macula tissue78, and a reduction in expression of glycolytic pathway 
genes following Müller cell ablation79. The former study observed a difference in 
expression of the enzyme phosphoglycerate kinase whose substrate is 3-
phosphoglycerate. We find an association with PHGDH, whose substrate is also 
3-phosphoglycerate (Figure 3), suggesting that both the glycolytic and serine 
pathways may be perturbed by PHGDH in the etiology of MacTel. 
 
Despite MacTel and diabetes being associated (reflected in our sample 
ascertainment; Table 1), our study finds very limited sharing of genetic risk at 
the five loci for the two disorders. Only the suggestive 3q21.3 locus has shown 
marginal association to clamp-based insulin sensitivity, whilst the other four loci 
have not been associated to any diabetes-related traits (Table 3). 
 
Here, we identified three validated and two suggestive loci with maximal 
observed odds ratio at each loci ranging from 1.43 to 2.46 for each additional 
risk allele. Risk factors of similar, and smaller, effect size have been discovered 
using GWASs for AMD72. Further risk factors for MacTel will likely be identified 
using additional cohorts. 
 
We report the first GWAS for MacTel and find genetic and metabolomic results 
implicating the glycine/serine metabolic pathway. We recognize that both 
glycine and serine may not be the actual driver metabolites for MacTel. However, 
they may still be useful biomarkers for pre-diagnostic screening in at-risk 
individuals, and our findings may lead to metabolite or enzymatic 
supplementation as a course for prevention or slowing disease progression. 
Further studies should validate these associations and determine if targeting 
those metabolites could become a useful strategy for screening or treatment. We 
also link MacTel with the glycolytic pathway, and confirm a reported link 
between MacTel and retinal venular caliber, thereby increasing our 
understanding of the disease. 
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http://genome.sph.umich.edu/wiki/LocusZoom_Standalone; SHAPEIT, 
https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html; 
IMPUTE2, https://mathgen.stats.ox.ac.uk/impute/impute_v2.html; 1000 
Genomes Project, http://www.1000genomes.org/; LINKDATAGEN, 
http://bioinf.wehi.edu.au/software/linkdatagen/; ExPASy84, 
http://www.expasy.org/; The Metabolomics GWAS Server, 
http://mips.helmholtz-muenchen.de/proj/GWAS/gwas/index.php; GTEx 
Project, http://gtexportal.org/ 
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Figure 1  Genome-wide plot of association. SNPs on sequential chromosomes are 
alternatively colored blue and orange. The x-axis is chromosomal position and 
the y-axis represents the –log10(P value) of association for each SNP to MacTel as 
tested by logistic regression with PC1 as a predictor to correct for population 
stratification. Analysis was performed with 476 MacTel cases and 1,733 controls. 
Red and blue horizontal lines are thresholds for genome-wide and suggestive 
association. 
  
 
Figure 2  Regional plots of association. (a-c) Association results are shown for 
the analyzed SNPs, along with recombination rates (blue lines) and the location 
of known genes (named blue horizontal lines), within the three loci associated 
with genome-wide significance at 1p12 (a), 2q34 (b), 5q14.3 (c). For each plot, 
the x-axis is scaled such that 100kb flanks each end of the loci as defined by the 
first and last SNP reaching suggestive significance (P < 10-5), and the y-axis 
represents the –log10(P value) of association for each SNP. Individual SNPs are 
represented as colored circles (genotyped) or crosses (imputed). For (a), (b) and 
(c), the sole purple circle represents the most significantly associated SNP at that 
locus in the discovery stage, and the other markers are colored according to their 
LD with that SNP. Recombination rates and LD are estimated from the EUR 1000 
Genomes Project March 2012 release, build hg19. 
  
 
 
Figure 3  Pathway analysis. Indicated are the enzymes encoded by genes 
associated to MacTel on chromosomes 1, 2, 3 and 7 (highlighted in red). A 
subsection of the glycolytic pathway highlights the enzyme encoded by PGK, 
whose differential expression has been observed in MacTel. The enzymes 
encoded by both PHGDH and PGK share the common substrate 3-
phosphoglycerate. Also shown is the position that carbonic anhydrase inhibitors, 
used to treat MacTel, may play in this pathway. For simplicity, common 
substrates (such as protons, water, NADH, NADPH, ATP and their derivatives) 
are not shown. Adapted from the ExPASy Bioinformatics Resource Portal84. 
  
 
Figure 4  Regional plots of association. (a-b) Association results are shown for 
the analyzed SNPs, along with recombination rates (blue lines) and the location 
of known genes (named blue horizontal lines), within the two loci associated 
with suggestive significance at 3q21.3 (a) and 7p11.2 (b). For each plot, the x-
axis is scaled such that 100kb flanks each end of the loci as defined by the first 
and last SNP reaching suggestive significance (P < 10-5), and the y-axis 
represents the –log10(P value) of association for each SNP. Individual SNPs are 
represented as colored circles (genotyped) or crosses (imputed). For (b) the sole 
purple circle represents the most significantly associated SNP at that locus in the 
discovery stage, and the other markers are colored according to their LD with 
that SNP, however for (a) the coloring is with respect to rs9880406. 
Recombination rates and LD are estimated from the EUR 1000 Genomes Project 
March 2012 release, build hg19. 
 
 
Table 1  Sample characteristics 
 
Sample Ntotal Nmales Nfemales Source* Age range in years$ % with 
diabetes# 
Discovery cases 476 192 284 MacTel Project 45-86 (mean=63.2, SD=8.04) 33.4 
Discovery controls 1,733 735 998 MacTel Project (Nsubtotal=76) 39-84 (mean=62.2, SD=10.64) 6.6 
AREDS (Nsubtotal=1657) 55-80 6.3 
Replication cases 172 74 98 MacTel Project 38-85 (mean=62.4, SD=8.45) 33.3 
Replication 
controls 
1,134 629 505 Columbia University controls (Nsubtotal=629) 74.8±7.1 - 
CCHMC controls (Nsubtotal=505) 2-52 - 
*MacTel Project consortium; AREDS: Age-Related Eye Disease Study; Columbia University controls; CCHMC: Cincinnati Children’s 
Hospital Medical Center; $Age extracted from the literature for AREDS, Columbia University controls and CCHMC controls; #Diabetes 
status for the Columbia University and CCHMC controls is unknown but presumed to be at baseline levels. 
 
 
  
Table 2  Significant associations of three robustly validated (a) and two suggestive (b) loci with MacTel in the discovery and 
replication stages 
 
a) 
 
Locus Most 
significant 
discovery 
stage SNP at 
locus 
(imputed?) 
OR (95% CI) 
P value# 
Gene(s) 
(genetic 
location) 
SNPs selected for replication 
SNP selected 
for 
replication 
(imputed?) 
Position$ 
(r2 LD to most 
significant 
SNP at locus) 
1000G 
minor 
allele 
(freq.)* 
Stage^ Minor allele frequency 
 
OR (95% CI) 
per 
minor allele# 
P value# 
 Cases Controls 
1p12 rs477992 
(yes) 
1.70 (1.47-1.97) 
P = 2.60 × 10-12 
PHGDH 
(intronic) 
rs539708 
(no) 
120208503 
(0.56) 
T 
(0.415) 
Discovery 0.4853 0.3904 1.42 (1.22-1.64) 2.82 × 10-6 
Replication 0.4394 0.3919 1.23 (0.91-1.67) 0.1761 
Meta-analysis 0.4774 0.3910 1.38 (1.21-1.57) 1.54 × 10-6 
rs666930 
(no) 
120258970 
(0.53) 
T 
(0.458) 
Discovery 0.5830 0.4602 1.60 (1.38-1.85) 4.02 × 10-10 
Replication 0.4949 0.4623 1.14 (0.85-1.54) 0.3744 
Meta-analysis^^ 0.5679 0.4610 1.39 (1.00-1.92) 0.047 
rs483180 
(yes) 
120267505 
(0.98) 
G 
(0.315) 
Discovery 0.4258 0.3021 1.68 (1.44-1.95) 1.59 × 10-11 
Replication 0.4142 0.3115 1.64 (1.26-2.13) 0.0002543 
Meta-analysis 0.4227 0.3046 1.67 (1.46-1.90) 1.76 × 10-14 
2q34 rs715 
(no) 
0.50 (0.42-0.60) 
P = 9.97 × 10-14 
CPS1 
(3’UTR) 
rs715 
(no) 
211543055 
(=) 
C 
(0.291) 
Discovery 0.1796 0.3090 0.50 (0.42-0.60) 9.97 × 10-14 
Replication 0.2135 0.3213 0.58 (0.40-0.82) 0.002384 
Meta-analysis 0.1853 0.3138 0.52 (0.44-0.61) 1.14 × 10-15 
rs4673553 
(no) 
211608379 
(0.41) 
G 
(0.458) 
Discovery 0.3466 0.4570 0.63 (0.55-0.74) 2.66 × 10-9 
Replication 0.3505 0.4641 0.62 (0.45-0.84) 0.002378 
Meta-analysis 0.3473 0.4598 0.63 (0.55-0.72) 2.38 × 10-11 
5q14.3 rs73171800 
(yes) 
2.41 (1.96-2.96) 
P = 7.74 × 10-17 
TMEM161-B 
/LINC00461 
(intergenic) 
rs17478824 
(no) 
87785624 
(0.97) 
T 
(0.086) 
Discovery 0.1775 0.0866 2.34 (1.90-2.87) 1.08 × 10-15 
Replication 0.2121 0.0855 2.94 (2.00-4.33) 3.90 × 10-8 
Meta-analysis^^ 0.1835 0.0861 2.47 (2.03-300) 1.09 × 10-19 
rs73173548 
(no) 
87813971 
(0.89) 
G 
(0.080) 
Discovery 0.1712 0.0796 2.46 (1.99-3.04) 1.16 × 10-16 
Replication 0.1667 0.0824 2.21 (1.48-3.32) 0.0001199 
Meta-analysis 0.1704 0.0807 2.40 (1.99-2.90) 7.27 × 10-20 
 
 
 
 
 
 
 
 
 
b) 
 
Locus Most 
significant 
discovery 
stage SNP at 
locus 
(imputed?) 
OR (95% CI) 
P value# 
Gene(s) 
(genetic 
location) 
SNPs selected for replication 
SNP selected 
for 
replication 
(imputed?) 
Position$ 
(r2 LD to most 
significant 
SNP at locus) 
1000G 
minor 
allele 
(freq.)* 
Stage^ Minor allele frequency 
 
OR (95% CI) 
per 
minor allele# 
P value# 
 Cases Controls 
3q21.3 rs9820286 
(yes) 
0.61 (0.49-0.75) 
P = 5.38 × 10-6 
ALDH1L1 
/KLF15 
(intergenic) 
rs9880406 
(no) 
126049305 
(0.88) 
A 
(0.199) 
Discovery 0.1345 0.1982 0.63 (0.52-0.77) 8.98 × 10-6 
Replication 0.1294 0.1898 0.63 (0.45-0.88) 0.00708 
Meta-analysis 0.1331 0.1949 0.63 (0.53-0.75) 2.07 × 10-7 
7p11.2 rs4948102 
(yes) 
1.46 (1.25-1.70) 
P = 2.25 × 10-6 
PSPH 
(intronic) 
rs4535700 
(no) 
56045448 
(0.94) 
T 
(0.258) 
Discovery 0.3319 0.2458 1.43 (1.22-1.67) 7.55 × 10-6 
Replication 0.3500 0.2687 1.44 (1.14-1.83) 0.002477 
Meta-analysis 0.3367 0.2548 1.43 (1.26-1.63) 6.54 × 10-8 
rs11238389 
(yes) 
56079744 
(1.00) 
A 
(0.273) 
Discovery 0.3398 0.2525 1.43 (1.23-1.68) 7.04 × 10-6 
Replication 0.3550 0.2992 1.28 (0.99-1.64) 0.05517 
Meta-analysis 0.3439 0.2649 1.39 (1.21-1.58) 1.42 × 10-6 
 
 
$Position in base pairs (bp) based on the hg19 reference genome, and the r2 linkage disequilibrium (LD) estimated from the discovery 
cohort sample genotypes; *Minor allele and frequency determined from the 1000Genomes project European population 
(http://1000genomes.org/); #ORs and P values derived from a logistic regression model, using PC1 as a covariate in the discovery stage; 
^Meta-analyses performed with random-effect modeling, although results for only two SNPs (^^) differed from fixed-effects modeling.  
Table 3  Directions of association of MacTel risks alleles with respect to metabolite levels, cis eQTLs and other traits for the 
three robustly validated (a) and two suggestive (b) loci 
 
a) 
 
MacTel 
risk loci 
Nearest genes Direction of effect with respect to MacTel risk haplotypes^ 
Increased Decreased 
1p12 PHGDH eQTL: ZNF697 (2) 
eQTL: PHGDH (1) 
serine 
eQTL: PHGDH (1) 
2q34 CPS1 fibrinogen 
betaine 
pyroglutamine 
glutaroyl carnitine 
homoarginine 
nitric oxide metabolites 
vasodilator response 
nitropusside induced bloodflow 
high-density lipoprotein 
glycine 
creatine 
N-acetylglycine 
X-08988 
serine 
glycine/threonine ratio 
homocysteine 
5q14.3 TMEM161-B/ 
LINC00461 
retinal venular caliber 
retinal arterial caliber 
eQTL: TMEM161B-AS1 (20) 
n/a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
MacTel 
risk loci 
Nearest genes Direction of effect with respect to MacTel risk haplotypes^ 
Increased Decreased 
*3q21.3 ALDH1L1/ 
KLF15 
clamp-based insulin sensitivity* 
glycine/serine ratio* 
delta-POST** 
incident ischemic stroke risk 
n/a 
7p11.2 PSPH delta-POST** 
eQTL: CCT6A (3) 
eQTL: GBAS (6) 
eQTL: NUPR1L (1) 
eQTL: PSPH (1) 
serine 
eQTL: SUMF2 (5) 
 
 
^ Direction of effect for cis eQTLs (observed in the given number of tissues) as derived from GTEx Project.  Metabolite levels as observed 
in blood plasma or serum. 
* At 3q21.3, the minor alleles of rs1107366 and rs10934753 were marginally associated with increased risk to MacTel. 
** Difference between pre- and post-methionine load test for circulating homocysteine levels (delta-POST) 
 
 
 
Online Methods 
 
Study population 
 
Our MacTel Project consortium (Supplementary Table 1) recruited cases and 
controls at 23 participating clinical centers in 7 countries (Australia, Germany, 
France, The UK, Switzerland, Israel, and the USA). Informed written consent was 
obtained in accordance with ethics protocols for human subjects approved by 
the appropriate governing body at each site in accordance with the Declaration 
of Helsinki. Protocols and records of consent were centrally managed by the 
EMMES Corporation (Rockville, Maryland). The following ethics boards granted 
approval for human subject enrollment; Quinze-Vingts, Paris, France: Comite De 
Protection Des Personnes Hopital Saint-Antonie; Centre for Eye Research, 
Victoria, Australia: The Royal Victorian Eye & Ear Hospital; Clinique 
Ophtalmolgie de Creteil, Paris, France: Comite De Protection Des Personnes 
Hopital Saint-Antonie; Hospital Lariboisiere, Paris, France: Comite De Protection 
Des Personnes Hopital Saint-Antonie; Jules Stein Eye Institute, UCLA,CA, USA: 
The UCLA Institutional Review Board; Lions Eye Institute, Nedlands, Australia: 
Sire Charles Gairdner Group Human Research Ethics Committee; Manhattan Eye, 
Ear & Throat Hospital, NY, USA: Lenox Hill Hospital Institutional Review Board; 
Moorfields Eye Hospital, London, UK: National Research Ethics Service; Retina 
Associates of Cleveland, Inc., Cleveland, USA: Sterling Institutional Review Board; 
Save Sight Institute, Sydney, Australia: South Eastern Sydney Illawarra Area 
Health Service Human Research Ethics Committee – Northern Hospital Network; 
Scripps Research Institute, La Jolla, USA: Scripps Institutional Review Board; St. 
Franziskus Hospital, Munster, Germany: Ethik-Kommission Der Arztekammer 
Westfalen-Lippe Und der Medizinishchen Fakultat der Westfallschen Wilhelms-
Universitat; The Goldschleger Eye Institute, Tel Hashomer, Israel: Ethics 
Committee The Chaim Sheba Medical Center; The New York Eye and Ear 
Infirmary, NY, USA: The Institutional Review Board of the New York Eye and Ear 
Infirmary; The Retina Group of Washington, Olympia, USA: Western Institutional 
Review Board; University of Bonn, Bonn, Germany: Rheinische Friedrich-
Wilhelms-Universitat Ethik-Kommission; University of Chicago, Chicago, USA: 
The University of Chicago Division of Biological Sciences – The Pritzker School 
Institutional Review Board; University of Michigan, Ann Arbor, USA: Medical 
School Institutional Review Board (IRBMED); University of Wisconsin, Madison, 
USA: Office of Clinical Trials University of Wisconsin School of Medicine and 
Public Health; The Wilmer Eye Institute of Johns Hopkins University, Baltimore, 
Maryland: Johns Hopkins School of Medicine Office of Human Subjects Research; 
Scheie Eye Institute University of Pennsylvania, Philadelphia, USA: University of 
Pennsylvania Office of Regulatory Affairs; University of Bern, Bern, Switzerland: 
Kantonale Ethikkommission Bern; John Moran Eye University of Utah, Salt Lake 
City, USA: The University of Utah Institutional Review Board; Bascom Palmer Eye 
Institute University of Miami, Miami, USA: The University of Miami Human 
Subjects Research Office; Columbia University, NY, USA: Columbia University 
Medical Center Institutional Review Board Category 4 waiver for research 
involving specimens obtained from de-identified subjects. Participants were 
given a standardized ophthalmic examination, including best corrected visual 
acuity, fundus photography, fluorescein angiography, optical coherence 
tomography, and blue light reflectance. Images were adjudicated at the Reading 
Center at Moorfields Eye Hospital, London. Diagnoses were made in accordance 
with the criteria described by Clemons et al. (2010)85 based on Gass and Blodi 
(1993)1. Retinal images were assessed for loss of transparency in the perifoveal 
region, dilated and telangiectatic blood vessels, especially in the temporal retina, 
and crystalline deposits. Participants are re-evaluated at regular intervals over 
the course of the study. MacTel Project consortium cases were used in both the 
GWAS discovery and replication stages. 
 
GWAS discovery stage control samples (Ntotal=1,733) were predominantly 
sourced from the Age-Related Eye Disease Study (AREDS, Nsubtotal=1,657)86,87. 
The remainder came from the MacTel Project consortium (Nsubtotal=76; most 
being spouses of MacTel cases) after confirmation as unaffected for MacTel by 
expert ophthalmologists. AREDS is a long-term natural history and clinical study 
of AMD and age-related cataracts. Patients were initially enrolled from 55-80 
years of age. We used the controls samples that, as described in dbGap 
(phs000429.v1.p1), “are all Caucasian, do not have age-related macular 
degeneration (AMD) and were further screened to also exclude individuals with 
cataracts, retinitis pigmentosa, color blindness, other congenital eye problems, 
LASIK, artificial lenses, and other eye surgery”. 
 
Replication stage control samples were of European ancestry and came from the 
electronic medical records and genomics (eMERGE) Cincinnati Children's 
Hospital Medical Center (CCHMC, Nsubtotal=505) study and Columbia University 
(Nsubtotal=629). The CCHMC controls were diagnosed with eosinophilic 
esophagitis, had an age range of 2-52, and had Illumina Omni5 SNP chip data 
available from dbGAP (project “Better Outcomes for Children: GWAS from 
Cincinnati Children's Hospital Medical Center (CCHMC) - eMERGE Phase II data”; 
phs000494.v1.p1)88. The Columbia University controls were confirmed as being 
of European ancestry by questionnaire during recruitment, have been used as 
controls for studies of age-related macular degeneration (AMD) as described 
previously72,89,90, were of an advanced age (mean age 74.8±7.1 years), did not 
exhibit any distinguishing signs of macular/retinal disease after clinical 
examination by trained ophthalmologists, and had no known family history of 
retinal disease. 
 
DNA sample preparation and quality control 
 
For MacTel Project consortium samples and Columbia University control 
samples, DNA was extracted from peripheral venous blood (Qiagen blood maxi 
kit 51194, Valencia, CA). DNA concentration was determined with the Qubit 
Fluorometer (Thermo Fisher Scientific, Waltham, MA). DNA samples of low 
purity were subjected to column purification (Qiagen blood and tissue kit 
69504). 
 
GWAS genotyping and quality control 
The GWAS discovery stage used a final cleaned dataset of 2,209 samples 
(Ncases=476; Ncontrols=1,733; Table 1). 
AREDS genotypes were obtained from NCBI’s dbGap (project “NEI Age-Related 
Eye Disease Study (AREDS) - Genetic Variation in Refractive Error Substudy”; 
phs000429 substudy of phs000001). AREDS samples were genotyped with the 
Illumina Omni2.5 SNP chips. Genotypes for 2,182,680 variants/probes for 1,657 
samples were downloaded from dbGap., and those with minor allele frequencies 
(MAFs) < 1%, or else monomorphic, were removed. Complementary bi-allelic 
(i.e. AT or CG) SNPs were removed due to strand uncertainty; these would 
otherwise cause problems when merging with the MacTel Project genotypes. For 
SNPs with identical chromosome identifiers and base-pair positions, only the one 
with least missingness was kept. Identity-by-descent (IBD) sharing was assessed 
using PLINK1.991,92 and a 0.04 kinship coefficient threshold was determined to 
establish independence of samples. Further filtering took place as described 
below in conjunction with the MacTel Project samples. 
 
From our MacTel Project cohort, a total of 704 samples (including MacTel cases 
and controls) were genotyped with the Illumina Omni5 SNP chip for the 
discovery stage. Illumina’s GenomeStudio software with default genotyping 
settings produced genotypes for a total of 4,641,218 variants/probes. DNA 
samples with <95% genotype call rate or unexpected or unusual sex-
chromosome call rates were flagged and removed. Monomorphic probes or 
variants with an MAF <1% were filtered out. Complementary bi-allelic (i.e. AT or 
CG) SNPs were removed due to strand uncertainty. For SNPs with identical 
chromosome identifiers and base-pair positions, only the one with least 
missingness was kept. Sample independence was tested by assessing IBD sharing 
using PLINK1.991,92 and applying a 0.04 kinship coefficient threshold. When IBD 
analysis suggested relatedness, a single sample was selected, usually being the 
sample with least missingness. 
 
AREDS and MacTel project SNP genotypes were merged and differential 
missingness was assessed between the two cohorts by Fisher’s exact tests and an 
exclusion threshold of P<0.001.  A mock GWAS was performed on the 76 MacTel 
Project consortium controls against the 1,657 AREDS controls.  A quantile-
quantile plot of this analysis shows little deviation between the expected and 
observed P values (Supplementary Figure 23). Further IBD analysis was 
performed to ensure no relatedness between AREDS and MacTel project 
samples. Principal component analysis (PCA) of the samples was performed with 
EIGENSOFT and PLINK to identify any population substructure (Supplementary 
Figures 2-4). This was achieved using 29,149 independent genome-wide SNPs 
selected with PLINK using the “--indep-pairwise” option; this assessed pairwise 
Pearson’s correlations (r) within windows of 1000 adjacent SNPs and greedily 
pruned these SNPs until no such pairs remained with r2 > 0.04, before sliding the 
window a further 50bp along. 
 
Imputation of SNPs was performed with SHAPEIT (v2.r790)93 and IMPUTE2 
(v2.3.2)94 following the software’s best practice guidelines. Reference genomes 
were obtained from the 1000 Genomes project95. Compare Figure 1 with 
Supplementary Figure 24 to see the effect of imputation on the GWAS results. 
 
Prior to statistical analysis, a final round of filtering removed any SNPs with >5% 
genotype missingness, a Hardy-Weinberg equilibrium exact test P < 10-6, or a 
minor allele frequency < 5%. 
 
GWAS statistical analysis 
 
For the discovery stage 2,209 samples (476 MacTel cases and 1,733 controls) 
with genotypes for 6,310,381 SNPs were analyzed by logistic regression with 
PLINK1.992. Principal component 1 (PC1) from the PCA was added to the logistic 
regression model as a covariate in the discovery stage. The scree plot indicated 
that additional PCs would have a negligible contribution (Supplementary 
Figure 3). Quantile-quantile plots (Supplementary Figure 5) and Manhattan 
plots (Figure 1 and Supplementary Figure 24) were created in R with the 
qqman package96. The top associated loci (P < 10-5) are summarized in 
Supplementary Tables 2 and 3. Local association plots (Figures 2 and 4) were 
constructed with LocusZoom97. The top SNP at each locus was also tested in 
PLINK using logistic regression with dominant and recessive modeling of the 
minor allele (A1) (Supplementary Table 5). 
 
GWAS power calculations 
 
We maximized the power of our GWAS discovery stage by using all MacTel 
Project cases available at the time. For GWASs of diseases such as MacTel, which 
are studied for the first time, it is not known what the expected effect size is. 
Power calculations were therefore performed post hoc with the Genetic Power 
Calculator98, assuming a population prevalence of 0.001, D’=1 (between risk 
marker and true causal marker), alpha=5 × 10-8 (significance level),  a range of 
genotypic relative risks and allele frequencies, and using the allelic test 
(Supplementary Figure 1). Given 476 cases and 1,733 controls, genotypic 
relative risks of 2 for genotype “Aa” and 4 for genotype “AA”, relative to the 
baseline genotype “aa”, and risk allele frequencies ranging from 0.20 to 0.60, 
would have > 0.99 power. However, genotypic relative risks of 1.5 and 2.25 for 
the genotypes “Aa” and “AA” would only a have peak power of 0.53 with a risk 
allele frequency of ~0.4, thus demonstrating the limit of our GWAS discovery 
stage. 
 
Replication analysis 
 
The six loci that reached genome-wide significance were selected for replication 
(Figure 2, Supplementary Figures 25-27, and Supplementary Table 2). Three 
of these loci were subsequently ruled as false positives after attempts to 
technically validate them on an independent genotyping platform (TaqMan 
assays; Applied Biosystems, Foster City, CA) yielded uncorrelated genotypes (i.e. 
a low concordance rate). We identified two further loci on chromosomes 3 and 7 
that showed suggestive evidence for association and warranted replication. This 
was based on their reported association to the serine and glycine metabolic 
pathways in other independent studies. Genotyping of the SNPs for replication at 
these five loci (three genome-wide significant and two suggestively associated) 
was performed by TaqMan assays in the new MacTel cases and Columbia 
University controls (Supplementary Figure 28). Assays were purchased from 
Applied Biosystems as validated, inventoried SNP assays-on-demand or were 
submitted to Applied Biosystems Assays-by-design pipeline. The choice of these 
SNPs for replication was limited by the ability to create TaqMan assays. 
Furthermore, we ensured that at least one actual genotyped, rather than 
imputed, SNP was selected at each locus. The genotyping technique used was 
identical to that described previously90. Briefly, 5-10ng of DNA were subjected to 
50 cycles on an ABI 9700 384-well thermocycler, and plates were read in an 
Applied Biosytems 7900 HT Sequence Detection System. CCHMC control 
genotypes were generated with the Illumina Omni5 platform (data was 
unavailable for rs483180 and rs11238389). 
 
Analysis in the replication cohort was performed with PLINK using a logistic 
regression framework and no covariates. 
 
Power calculations were performed for the replication analysis. Given a 
replication cohort of 172 cases and 1134 controls, a population prevalence of 
0.001, alpha=0.01, D’=1 (between risk marker and true causal marker), and the 
ORs and allele frequencies of the top SNP at each loci, we estimated >97% power 
to replicate the top 3 genome-wide significant loci with the allelic test. At the two 
suggestively significant associated loci, 3q21.3 and 7p11.2, the powers were 
0.5943 and 0.7033, respectively. 
 
Meta-analysis 
 
Given the differences in ascertainment of the controls used for the discovery and 
replication stages, and that a covariate was applied to the discovery stage 
analysis but not the replication stage, meta-analyses between the discovery and 
replication stages for the top hits were performed with a random-effects model 
in PLINK as previously described99 (Table 2). Only two of the 10 SNPs tested 
showed signs of differing effect sizes between the discovery and replication 
cohorts, while the results for the other 8 SNPs were identical to modeling by 
fixed-effects. 
 
Heritability estimates 
 
Heritability on the liability scale was estimated using a linear mixed model 
method, developed by Yang et al. (2010)100 and adapted for dichotomous traits 
by Lee et al. (2011)101, applied to the 1,093,805 directly genotyped SNPs from 
the discovery stage (i.e. no imputed SNPs). Applying a population prevalence of 
0.0045% and 0.1%, yielded h2 of 0.21 and 0.74 respectively, with 5% of this h2 
explained by our five replicated loci (for both prevalence rates). 
 
Prediction Modeling 
 
Logistic regression prediction modeling was performed in R with the GWAS 
discovery stage cohort, using the strongest associated SNP that replicated at each 
of the five loci as predictors and with PC1 and sex as covariates (Supplementary 
Table 6 and Online methods). Initially, a variable selection procedure 
investigated the relevance of the interaction terms between gender and the SNPs 
and any epistatic effects. Once a stable model was selected its predictive power 
was assessed. The genotypic effect for all markers was modeled as additive to be 
consistent with the discovery stage. We have shown that the additive model best 
describes the loci at chromosome 1, 2, 5 and 7, and there is marginal difference 
for the chromosome 3 loci between the additive and recessive models 
(Supplementary Table 5). To account for possible population stratification, we 
included the PC1 using orthogonal polynomials of degree three (PC1_1, PC1_2 
and PC1_3). Starting with the “full” model, the variable selection step was 
performed using backward stepwise regression until convergence was achieved 
as measured by the Bayesian Information Criterion (BIC). Five fold cross 
validation (CV) was used to perform the variable selection with random subsets 
of the initial data, initialized multiple times with 100 different seeds. The case 
and control status was blinded for the performance testing of the prediction 
model via an automated procedure in R. In total 11 different models were 
observed from all 500 fitted models. One model predominated, being selected 
~66% of times, that included the main effects for all 5 SNPs, PC1 and the 
interaction term between gender and the SNP on chromosome two (column 
four in Supplementary Table 6). We did not observe any significant epistatic 
effect between SNPs. Using the R package ROCR102, a ROC curve was plotted for 
this model with an “Area Under the ROC Curve” (AUC) of 0.719 (and without PC1 
an AUC of 0.707; Supplementary Figure 13). 
 
Since PC1 was unavailable in the replication cohort (due to lack of genotype 
data), this prediction model was applied to our replication cohort for validation 
after assessing the estimated effects of each SNP in the discovery cohort without 
PC1. We achieved an AUC of 0.679 thereby validating our results from the 
discovery cohort (Supplementary Figure 14). 
 
Sex specific ORs at 2q34 
 
At 2q34 we derived sex specific ORs for the top most associated SNP (rs715) by 
performing logistic regression in R with orthogonal polynomials of degree three 
for PC1 (Supplementary Table 4).  Considering the risk allele (which is the 
major allele), we find a borderline significant effect size in males (per-allele OR = 
1.40, 95% CI = 1.08-1.81) and a significant association in females (per-allele OR = 
2.58, 95% CI = 2.00-3.36). 
 
Metabolomics analysis 
 
Serum was collected from 50 MacTel cases and 50 controls from the wider 
MacTel Project cohort. Samples were well matched with regards to gender (25 
females and 25 males in both cases and controls), age (average of 64 years in the 
MacTel cases and 63 years in the controls), diabetic status (38 non-diabetics and 
12 type-2 diabetics in both cases and controls) and ethnicity (48 Caucasians 
MacTel cases and 47 Caucasian controls). All individuals fasted overnight and 
blood was taken before noon. Around 5ml of blood was collected in a clot 
activating vacutainer tube (Vacutainer Plastic SST II Advance Tube with Gold 
Hemogard Closure, Becton Dickinson), left at room temperature for 30min and 
then centrifuged for 5 min at 1200g. The supernatant was collected, frozen and 
stored at -80°C. Levels of 1,281 metabolites in the serum were measured by 
Metabolon (Durham, USA). Briefly, this involved initial protein precipitation with 
methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) 
followed by centrifugation. The resulting extract was analyzed by reverse phase 
ultrahigh performance liquid chromatography/tandem mass spectrometry 
(UPLC-MS/MS) with positive ion mode electrospray ionization (ESI). Peaks were 
quantified using the area-under-the-curve technique. Quality controls steps were 
applied to the 1,281 log2 transformed metabolite levels, thereby removing 403 
for high missingness (>10% missing data for either MacTel cases or controls), 30 
for high correlation (|Pearson’s r| ≥ 0.95) between any pair of metabolites, and 
49 with abnormal distributions, thereby leaving a total of 799 metabolites for 
analysis. Missing metabolite data was then imputed with the minimum value for 
each metabolite across all samples. Quantile normalization of the data was 
performed using the R package limma103. Metabolite levels were then compared 
between the MacTel cases and controls by Student’s T-tests. 
 
eQTL analysis 
 
The 419 variants showing at least suggestive association (P < 10-5) to MacTel at 
the five loci were tested for association to cis gene expression levels in at least 40 
tissues from 572 donors. Here, cis is defined as being within +/- 1Mb of the 
transcription start site of each gene. GTEx returns eQTL association results that 
are beyond specific gene-and-tissue derived significance thresholds. 
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